News Search Results
Jun 12, 2025, 08:00 ET Ouro Medicines Announces a Clinical Trial of OM336 for Autoimmune Cytopenias Following Positive Case Reports in The New England Journal of Medicine
SAN FRANCISCO, June 12, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic, immune-mediated diseases, today announced plans to initiate a multi-national
More news about: Ouro Medicines
Jun 12, 2025, 08:00 ET Arthrosi Presents Positive Long-Term Safety and Efficacy Data for Pozdeutinurad (AR882) at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025
DIEGO, June 12, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels,
More news about: Arthrosi Therapeutics
Jun 12, 2025, 07:00 ET Synthego Prevails In Patent Appeal Confirming Agilent CRISPR Patents Are Invalid
researchers and therapeutic developers to continue to drive successful patient outcomes. About SynthegoSynthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health.
More news about: Synthego
Jun 12, 2025, 06:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
B-cell malignancies and earlier lines of therapy. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company
More news about: ADC Therapeutics SA
Jun 12, 2025, 05:00 ET Industrial Enzymes Market worth $12.01 billion by 2030- Exclusive Report by MarketsandMarkets™
environmental concerns have prompted industries to adopt enzyme-based solutions for water treatment and pollution control. Government support for biotechnology and bioeconomy development, such as India's BioE3 policy launched in August 2024,
More news about: MarketsandMarkets
Jun 12, 2025, 03:32 ET Aquaporin appoints Chief Executive Officer
Directors of Aquaporin A/S ("Aquaporin" or the "Company"), an innovative water technology company dedicated to rethinking water filtration with biotechnology, is delighted to announce the appointment of Ulrik Lund Jakobsen as the new Chief Executive Officer of Aquaporin
More news about: Aquaporin A/S
Jun 12, 2025, 03:22 ET Aquaporin appoints Chief Executive Officer
Directors of Aquaporin A/S ("Aquaporin" or the "Company"), an innovative water technology company dedicated to rethinking water filtration with biotechnology, is delighted to announce the appointment of Ulrik Lund Jakobsen as the new Chief Executive Officer of Aquaporin
More news about: Aquaporin A/S
Jun 12, 2025, 02:00 ET Fortune Unveils First-Ever Europe's Most Innovative Companies List
personalization tools and biological skin age technology to generate custom skincare recommendations. Unilever is second for pioneering work in biotechnology and its new AI-assisted laundry detergent. "There's a misconception that Europe is not innovative," said
More news about: Fortune Media (USA) Corporation
Jun 12, 2025, 02:00 ET Real-world prospective data confirms improved risk stratification in multiple myeloma using SKY92 gene expression profiling
(LDT) from SkylineDx's CAP/CLIA lab in San Diego (CA, USA). About SkylineDx SkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology, inflammatory, and infectious diseases. SkylineDx uses its expertise
More news about: SkylineDx
Jun 12, 2025, 01:44 ET Shareholder Alert: Robbins LLP Informs Investors of the Rocket Pharmaceuticals, Inc. Class Action
between February 7, 2025 and May 26, 2025. Rocket is a fully integrated, late-stage biotechnology company focused on the development of gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating
More news about: Robbins LLP
Jun 11, 2025, 23:46 ET Intensity Therapeutics, Inc. Announces Pricing of Public Offering
June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
More news about: Intensity Therapeutics Inc.
Jun 11, 2025, 17:31 ET Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast Period (2025-2034) | DelveInsight
the key multiple sclerosis companies, including Sanofi, Immunic, InnoCare Pharma, Tiziana Life Sciences, Biogen, Bristol-Myers Squibb, ImStem Biotechnology, Idorsia Pharmaceuticals, among others.
More news about: DelveInsight Business Research, LLP
Jun 11, 2025, 16:06 ET Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
More news about: Intensity Therapeutics Inc.
Jun 11, 2025, 13:24 ET Blue Water Acquisition Corp. III Announces Closing of Upsized $253 Million Initial Public Offering
business, industry, sector or geographical location, the Company intends to focus on high-potential companies in the artificial intelligence (AI), biotechnology, healthcare and technology sectors. Forward-Looking Statements This press release contains statements that constitute "forward-looking
More news about: Blue Water Acquisition Corp iii
Jun 11, 2025, 13:04 ET Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
June 11, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch,
More news about: Northwest Biotherapeutics, Inc.
Jun 11, 2025, 12:49 ET Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
June 11, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch,
More news about: Northwest Biotherapeutics, Inc.
Jun 11, 2025, 10:00 ET Specific Biologics Welcomes Paul J. Hastings as Chair of the Board of Directors
gene therapy company, and recently served as the Chair of the Biotechnology Innovation Organization (BIO). Over his career, he has held numerous top leadership roles, including CEO of OncoMed, QLT, Axys Pharmaceuticals, and LXR Biotechnology, and President of Chiron BioPharmaceuticals. He has guided corporate
More news about: Specific Biologics Inc.
Jun 11, 2025, 09:30 ET "STRONGER TOGETHER": SWITZERLAND CHAMPIONS INTERNATIONAL PARTNERSHIPS AS KEY TO ACCELERATED INNOVATION", ONCE AGAIN SWITZERLAND IS SHOWCASING ITS BIOTECH EXCELLENCE AT BIO INTERNATIONAL IN BOSTON 16-19 JUNE, 2025
Provides laboratory services, R&D, and consulting to foster innovation in biotechnology.
More news about: Swiss Business Hub USA
Jun 11, 2025, 08:30 ET Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study
June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
More news about: Intensity Therapeutics Inc.
Jun 11, 2025, 08:30 ET TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient
June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with
More news about: TC BioPharm
Jun 11, 2025, 08:00 ET Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)
June 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics, today announced the publication of transformative preclinical research in the journal
More news about: Kazia Therapeutics Limited
Jun 11, 2025, 07:46 ET Ping An Good Doctor Revamps Brand and Launches Annual Healthcare Service Brand
Healthcare Frontier technology is changing the world at an astonishing pace, and the digital intelligence era, driven by artificial intelligence and biotechnology, has arrived. Under the guidance and promotion of various national policies, medical AI has gradually entered an important strategic position for
More news about: Ping An Healthcare and Technology Company Limited
Jun 11, 2025, 07:32 ET Ping An Good Doctor Revamps Brand and Launches Annual Healthcare Service Brand
Healthcare Frontier technology is changing the world at an astonishing pace, and the digital intelligence era, driven by artificial intelligence and biotechnology, has arrived. Under the guidance and promotion of various national policies, medical AI has gradually entered an important strategic position for
More news about: Ping An Healthcare and Technology Company Limited
Jun 11, 2025, 07:00 ET Benchling Announces Collaboration with Merck on Vaccine Bioanalysis
throughout the development process." About Benchling Benchling creates the software that powers the biotechnology industry, serving cutting-edge start-ups and more than half of the top 50 global biopharma companies. Over 200,000 scientists rely on the Benchling
More news about: Benchling
Jun 11, 2025, 07:00 ET Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
long-term incentives with the creation of shareholder value. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.